Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Growing Regulatory Approvals for Non-Hodgkin Lymphoma
4.1.1.2. The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs
4.1.2. Restraints
4.1.2.1. Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma
4.1.3. Opportunity
4.1.3.1. Exploring Combination Therapies for Enhanced Non-Hodgkin Lymphoma Treatment
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. B-cell Lymphomas*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. T-cell Lymphoma
9. By Drug Class
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Monoclonal Antibodies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antibody-Drug Conjugates
9.4. BTK/BCL-2 Kinase Inhibitors
9.5. PI3 Kinase Inhibitors
9.6. Protease Inhibitors
9.7. PD1 Inhibitors
9.8. Immunomodulatory Drugs
9.9. Chemotherapy Agents
9.10. CAR T-Cell Therapy
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Parenteral
10.4. Others
11. By Distribution Channel
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. The U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. The U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. Brazil
12.4.7.2. Argentina
12.4.7.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. China
12.5.7.2. India
12.5.7.3. Japan
12.5.7.4. Australia
12.5.7.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. AbbVie, Inc. (Pharmacyclics LLC) *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. AstraZeneca plc
14.3. Bayer AG
14.4. Bristol-Myers Squibb Company (Celgene Corp.)
14.5. Gilead Sciences, Inc. (Kite Pharma)
14.6. Johnson & Johnson (Janssen Biotech, Inc.)
14.7. Merck & Co., Inc.
14.8. Novartis AG
14.9. Roche Holding AG (F. Hoffmann-La Roche AG)
14.10. Seagen, Inc. (Seattle Genetics, Inc.)
14.11. Takeda Pharmaceutical Co., Ltd.
14.12. Teva Pharmaceutical Industries Ltd.
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us